STAT3 and esophageal squamous cell carcinoma: Fichter et al. have found that ErbB inhibitors could inhibit cell migration of ESCC cells through distinct signaling pathways (ERK1/2, Akt, STAT3, and RhoA), suggesting the powerful clues for developing ErbB targeted therapies.